Physician profile
James W Smith
NPI 1700820701
$1,812.94
in general payments reported to CMS, 2019-2025
13 companies · $212 in 2025
The $212 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2021: $136 · 2022: $287 · 2023: $381 · 2024: $334 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $927.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $383.65 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $234.53 | 2019-2024 | Stelara |
| Abbvie INC. | $204.46 | 2019-2025 | |
| Biogen, INC. | $150.00 | 2019 | |
| Enterra Medical, INC. | $143.81 | 2022-2023 | |
| Janssen Biotech, INC. | $140.85 | 2022-2024 | Tremfya, Stelara |
| Kestra Medical Technology Services, INC. | $130.30 | 2024-2025 | Assure Wcd |
| Evoke Pharma, INC. | $125.00 | 2023 | Gimoti |
| Alnylam Pharmaceuticals INC. | $104.16 | 2021 | |
| Boston Scientific Corporation | $85.94 | 2019 | |
| Pfizer INC. | $56.72 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $33.06 | 2025 | Dupixent |
| Ardelyx, INC. | $20.46 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.